Top Markets
Coin of the day
Össur hf. Össur hf.

Össur hf.

OSSR
株式のランク #7162
Össur hf. and its subsidiaries are actively involved in the creation,... Össur hf. and its subsidiaries are actively involved in the creation, advancement, manufacturing, and global distribution of non-invasive orthopedic medical devices. Their reach extends across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's operations are divided into two main business units: Prosthetics and Bracing & Supports. The Prosthetics division supplies both mechanical devices, such as lower limb and finger prostheses, and cutting-edge bionic products. These bionic solutions, designed for amputees, incorporate microprocessor-controlled feet, knees, hands, liners, and other integrated components featuring sensors, computing power, intrinsic intelligence, and actuators. In contrast, the Bracing & Supports segment offers a variety of supportive equipment for areas like the spine, knees, hips, feet, ankles, and hands. These products serve both therapeutic and preventative purposes by stabilizing joints and other body parts, in addition to providing injury management solutions to aid the healing of fractures and ligament injuries. Össur's primary customer base consists of specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgical centers. The company distributes its offerings through a combination of its own direct sales force and a network of third-party distributors. Founded in 1971 and headquartered in Reykjavik, Iceland, Össur hf. operates as a subsidiary of William Demant Invest A/S.
株価
$4.26
最終同期: 2024-05-03
時価総額
$1.70B
変化(1日)
0.99%
変化(1年)
0.00%
IS
取引 Össur hf. (OSSR)

カテゴリー

Össur hf.(OSSR)の収益
Aug 2026 時点の収益 TTM: 0
Össur hf. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Össur hf. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE